Empasiprubart

7 trials 3 recruiting

Filter these 7 trials by condition, phase, country and more.

Open in Search →

7 Registered trials

3 Recruiting

4 Completed trials

1 Sponsors

23 Countries

Phase III

Phase II

Phase III: 3 Phase II: 4

Indications tested

Multifocal motor neuropathy 2 Delayed graft function 1 Myasthenia gravis 1 Dermatomyositis 1

Sponsors using this IMP

All trials

7 total

MP: ADAPT Forward - Master protocol of a platform study to evaluate the safety and efficacy of multiple regimens in participants with Myasth… Recruiting

2025-522492-28-00 Phase II 7 countries Argenx
A study to assess the efficacy and safety of empasiprubart in adults with CIDP Recruiting

2025-520805-10-00 Phase III 15 countries Argenx
A study to assess efficacy and safety of empasiprubart versus IVIg in adults with CIDP ("emvigorate") Recruiting

2024-520097-36-00 Phase III 19 countries Argenx
A study to assess the efficacy and safety of Empasiprubart versus IVIg in adults with Multifocal Motor Neuropathy Ended

2024-516473-72-00 Phase III 19 countries Argenx
ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft Function (Varvara) Ended

2022-503091-89-00 Phase II 7 countries Argenx
A clinical trial to investigate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of A… Ended

2023-507052-69-00 Phase II 8 countries Argenx
A study to evaluate safety and efficacy of Empasiprubart in adults with Dermatomyositis Ended

2023-508337-14-00 Phase II 4 countries Argenx

Showing 1–7 of 7 trials

← All drugs A–Z